Amended Current Report Filing (8-k/a)
June 11 2018 - 4:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K/A
Amendment
No. 1
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 28, 2018
EyePoint Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51122
|
|
26-2774444
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
480 Pleasant Street
Watertown, MA
|
|
02472
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617)
926-5000
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 2.01 Completion of Acquisition or Disposition of Assets.
On March 29, 2018, EyePoint Pharmaceuticals, Inc. (the Company), formerly pSivida Corp., filed a Current Report on Form
8-K
(the
Original Form 8-K)
disclosing that the Company and its newly-created wholly-owned subsidiary, Oculus Merger Sub, Inc. (Merger Sub),
entered into an Agreement and Plan of Merger (the Merger Agreement) with Icon Bioscience, Inc., a Delaware corporation (Icon) and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its
capacity as representative of Icons securityholders, pursuant to which Merger Sub was merged with and into Icon, with Icon being the surviving corporation and a wholly-owned subsidiary of the Company (the Icon Acquisition). This
amendment to the Original Form
8-K
is being filed for the purpose of satisfying the Companys undertaking to file the financial statements and pro forma financial information required by Item 9.01 of
Form
8-K,
and this amendment should be read in conjunction with the
Original Form 8-K.
Item 8.01 Other Information.
Attached hereto as
Exhibit 99.2 is a description of the Companys business following the Icon Acquisition, which description replaces the disclosures contained in the Companys prior public filings, including those appearing under the caption
Business in its Annual Report on Form
10-K
for the fiscal year ended June 30, 2017 filed with the Securities and Exchange Commission (SEC) on September 13, 2017, as amended by
its Annual Report on Form
10-K/A
for the fiscal year ended June 30, 2017 filed with the SEC on October 30, 2017.
Item 9.01 Financial Statements and Exhibits.
(a)
|
Financial Statements of Businesses Acquired
|
The audited balance sheets of Icon as of December 31,
2017 and 2016, and the related statements of operations, stockholders equity (deficit) and cash flows for each of the years in the
two-year
period ended December 31, 2017, including the report of
its independent registered public accountant, Frank, Rimerman + Co. LLP, are filed as Exhibit 99.3 to this Form
8-K/A
and incorporated herein by reference.
(b)
|
Pro Forma Financial Information
|
The unaudited pro forma condensed combined financial information
related to the Icon Acquisition is filed as Exhibit 99.4 to this Form
8-K/A
and incorporated herein by reference.
(d) Exhibits
|
|
|
Exhibit
No.
|
|
Description
|
|
|
4.1
|
|
Warrant to Purchase Common Stock of pSivida Corp., issued March
28, 2018, to SWK Funding LLC (incorporated herein by reference to Exhibit 4.1 to the Registrants Current Report on Form
8-K
filed on March 29, 2018 (File
No.
000-51122)).
|
|
|
10.1
|
|
Securities Purchase Agreement, dated as of March
28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare
Partners-A,
L.P. (incorporated herein by reference to Exhibit 10.1 to the Registrants Current Report on Form
8-K
filed on March 29, 2018 (File
No. 000-51122)).
|
|
|
10.2
|
|
Second Securities Purchase Agreement, dated as of March
28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare
Partners-A,
L.P. and each other person identified on the signature pages thereto (incorporated herein by reference to Exhibit
10.2 to the Registrants Current Report on Form
8-K
filed on March 29, 2018 (File
No. 000-51122)).
|
|
|
10.3
|
|
Registration Rights Agreement, dated as of March
28, 2018, by and among pSivida Corp. and EW Healthcare Partners, L.P. and EW Healthcare
Partners-A,
L.P. (incorporated herein by reference to Exhibit 10.3 to the Registrants Current Report on Form
8-K
filed on March 29, 2018 (File
No. 000-51122)).
|
|
|
|
|
|
10.4
|
|
Credit Agreement, dated as of March
28, 2018, among pSivida Corp., SWK Funding LLC and the financial institutions party thereto from time to time as lenders (incorporated herein by reference to Exhibit 10.4 to the Registrants Current Report on Form
8-K
filed on March 29, 2018 (File
No. 000-51122)).
|
|
|
10.5
|
|
Agreement and Plan of Merger, dated March
28, 2018, by and among pSivida Corp., Oculus Merger Sub, Inc., Icon Bioscience, Inc. and Shareholder Representative Services LLC (incorporated herein by reference to Exhibit 10.5 to the Registrants Current Report on Form
8-K
filed on March 29, 2018 (File
No. 000-51122)).
|
|
|
23.1*
|
|
Consent of Frank, Rimerman + Co. LLP.
|
|
|
99.1
|
|
Press release dated March 28, 2018 (incorporated herein by reference to Exhibit 99.1 to the Registrants Current Report on Form
8-K
filed on March 29, 2018 (File
No. 000-51122)).
|
|
|
99.2*
|
|
Updated Business Section.
|
|
|
99.3*
|
|
Audited financial statements of Icon Bioscience, Inc.
|
|
|
99.4*
|
|
Unaudited pro forma condensed combined financial statements.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
EyePoint Pharmaceuticals, Inc.
|
|
|
|
|
Date: June 11, 2018
|
|
|
|
By:
|
|
/s/ Nancy Lurker
|
|
|
|
|
Name:
|
|
Nancy Lurker
|
|
|
|
|
Title
|
|
President and Chief Executive Officer
|
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Historical Stock Chart
From Apr 2023 to Apr 2024